Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798948 | 1.00 | GAA (0.53) | GAAALDH1A1CA1CA2NOX4 | |
| SCHEMBL6798750 | 1.00 | GAA (0.53) | GAAALDH1A1CA1CA2NOX4 | |
| SCHEMBL6802680 | 0.92 | GAA (0.64) | GAAALDH1A1CA1CA2CNR1 | |
| SCHEMBL6802677 | 0.92 | GAA (0.64) | GAAALDH1A1CA1CA2CNR1 | |
| SCHEMBL6807150 | 0.92 | CA1 (0.48) | GAAALDH1A1CA1CA2NOX4 | |
| SCHEMBL6807148 | 0.92 | CA1 (0.48) | GAAALDH1A1CA1CA2NOX4 | |
| SCHEMBL6803651 | 0.91 | NOX4 (0.48) | NOX4TYRACHEHDAC1HDAC6 | |
| SCHEMBL6797880 | 0.91 | ALDH1A1 (0.52) | GAAALDH1A1CA1CA2NOX4 | |
| SCHEMBL6807707 | 0.91 | MAPT (0.48) | ALDH1A1CA1CA2NOX4TYR | |
| SCHEMBL6803649 | 0.91 | NOX4 (0.48) | NOX4TYRACHEHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762321-B2 | SUCH AS N-(2-(3,4-DIMETHOXYPHENYL)ETHYL)-3-DIFLUOROMETHOXY-2-(4 -METHYLPHENYL)ACRYLAMIDE; FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-13 | — | — | US | disclosed |
| US-20030195354-A1 | Amide compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1295868-A1 | AMIDE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195354-A1 | Amide compounds and use thereof | CBR1, CBR3, NAT1 | GAA 2282/4885ALDH1A1 244/4885CA1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.